Is a "Free" OEM Formula Too Good to Be True? 8 Advanced Questions Brand Owners Ask About Cosmetic Contract Manufacturing
Picking a factory is only step one. What keeps brand owners up at night are the things below the surface — contract clauses, formula ownership, packaging mismatches. This week we collected the 8 most frequent advanced questions from brand owners and answered them end to end, from legal compliance to hands-on production details.
Q1: A factory says the "formula is free" — is that legit?
Short answer: Yes, but only if you understand what "free" actually costs you.
A "free formula" means the factory picks a finished formula from its formula library and makes it under your brand. In the international industry this is called ODM (Original Design Manufacturing) — the factory supplies both the formula and the production line; you only handle brand and channel.
Why factories give it away "free": they have already amortized the R&D cost across the mass-production price. When you order at a 500-unit MOQ, your per-unit material cost is 15%–30% lower than a brand-developed formula, because the factory buys raw materials at scale (e.g., a bulk hyaluronic acid buyer gets far better pricing than a spot purchaser).
But "free" ≠ "yours." Three things to clarify:
Our take: Startups can absolutely use a free ODM formula for the first batch to validate the market fast. But once you pass ~USD 1.4M annual revenue, move to an exclusive OEM formula to build your moat — if your hero product shares a formula with a competitor, you have zero differentiation when they start a price war.
Q2: Will buying raw materials yourself and having the factory process them actually save money?
Short answer: Theoretically 5%–15% cheaper; in practice it often costs you more.
The math looks simple: buy niacinamide direct from a major supplier, save per kilo; buy retinol direct, save per kilo. So why not self-source and have the factory produce?
Three pitfalls that bite more often:
- Factory may reject toll manufacturing. A compliant factory (with manufacturing license + ISO 22716) must run its own incoming quality control (IQC) on your materials. Non-conforming batches get returned — you eat round-trip freight plus lost production slots.
- Spec mismatch. Your niacinamide is 99.5% pure; the factory's acceptance spec is 99.8%. A 0.3-point gap = rejection. Worse: microbial overage from a trader's "leftover" stock means outright refusal.
- Regulatory source consistency. Under MoCRA (US) and EU 1223/2009, the ingredient supplier declared at registration must match what's actually used. Swap suppliers mid-stream and you may trigger a formula-change refiling.
Our take: Unless you're an insider in the raw-material trade, don't self-source. Let the factory handle everything (turnkey). Their scale pricing plus QC system is worth far more than the small raw-material delta you'd save.
Q3: Who decides a product's shelf life? What's the basis for a 3-year claim?
Short answer: Not opinion — stability test data decides it.
The default 3-year shelf life isn't arbitrary; it sits on a full accelerated stability testing system. A standard protocol (aligned with ICH Q1A and common industry practice) includes:
Passing 6-month accelerated testing = permission to claim 3 years — the industry norm. But if accelerated testing shows separation, discoloration, off-odor, or pH drift beyond 0.5, the factory must shorten to 2 years or reformulate.
Three things to watch: (1) contractually require the stability report delivered with the bulk order; (2) active-ingredient products may need shorter claims — a high-strength vitamin C (ethyl ascorbic 2%–3%) is usually labeled 2 years, and retinol loses 15%–20% potency after 6 months; (3) packaging matters — acrylic jars are oxygen-permeable (shorten claim), airless pumps seal fully (keep full claim).
Q4: Should the brand or the factory run the efficacy substantiation, and who pays?
Short answer: Legally the brand is responsible; operationally you can split it with the factory.
Under MoCRA, cosmetic claims must be substantiated with adequate evidence — and in the EU, claims must comply with the common criteria (Reg. 655/2013) and sit in the Product Information File (PIF) with the CPSR.
Division of labor: the factory typically owns the safety assessment (toxicology, micro, heavy metals) — covered in the bulk price. The brand must own human efficacy testing at a CMA/CNAS-equivalent lab, with the report titled in the brand's name. Shared ODM formulas can split efficacy costs across brands (USD 400–1,100 / brand license fee).
Our take: Pin down efficacy-cost ownership in the contract before signing. Brands often discover at filing stage that human testing is required and blow the budget. Plan ahead: for brightening/sunscreen, efficacy can be 10%–15% of first-order budget.
Q5: How many SKUs should a new brand launch with?
Short answer: 3–5 SKUs — 1 traffic SKU + 1–2 margin SKUs + 1–2 image SKUs.
Three data points support this count: (1) MOQ capital — at 1,000 units/SKU, first order is ~USD 28,000–35,000, within reach for a new brand; (2) TikTok/Amazon seeding efficiency — 3–5 SKUs support 15–20 pieces of content; (3) repurchase loop needs at least 3 SKUs to work.
Two warnings: ⚠️ don't launch sunscreen first (US FDA OTC / EU special category, 3–6 month lead, high cost); ⚠️ don't launch color cosmetics first (12 shades = 12 SKUs of filing + inventory).
Q6: Packaging MOQ is 10,000 but formula MOQ is only 500 — how do I bridge that gap?
Short answer: This "packaging/formula mismatch" is the most common OEM headache. Three solutions.
Packaging and formula are two different supply chains. A mold-based packaging plant needs 5,000–10,000 units to amortize tooling; formula production is flexible at 500. The MOQ gap is 10–20×.
Solution 1 — Order packaging MOQ, warehouse the surplus (recommended): 10,000 bottles + first 1,000 filled. Remaining 9,000 empty bottles sit in the factory warehouse; next reorder just fills — no 15–25 day packaging wait. ✅ fast reorder (7–10 days) ❌ capital tied in packaging (USD 4,200–11,200 for 10k serum bottles).
Solution 2 — Brand buys packaging, ships to factory for fill: lower MOQ (5,000), 10%–20% cheaper per unit, but carries tolling IQC risk.
Solution 3 — Downgrade packaging spec: drop custom-color glass (MOQ 10,000) for stock transparent bottles (MOQ 1,000), or switch tube printing to labeling (MOQ 500). ✅ minimal capital ❌ lower differentiation.
Our take: Use Solution 3 at 0→1, switch to Solution 1 once validated, leave Solution 2 for teams with supply-chain experience.
Q7: How should a brand negotiate the "formula IP" clause in the contract?
Short answer: Four clauses must be nailed down in writing, or you'll regret it.
Formula IP is where OEM contracts fight the most. Many brand owners sign the factory template with "formula IP belongs to factory" and only discover later the factory sold the same formula to a competitor.
Clause 1 — Ownership: ODM → factory owns, brand gets usage (acceptable); OEM → brand owns, must state "factory shall not supply this formula to any third party."
Clause 2 — Exclusivity: even under ODM you can negotiate regional / category / time exclusivity (e.g., "exclusive in mainland China for 3 years").
Clause 3 — Modified formula ownership: if the brand requests a tweak (niacinamide 3%→5%), the modified formula should belong to the brand. Suggested wording: "Any modification made by the manufacturer at the brand's written request shall have its IP vest in the brand; the manufacturer shall not use or disclose it."
Clause 4 — Post-termination use: the brand should retain perpetual rights to a bought-out formula and may commission any qualified manufacturer. Suggested wording: "Upon termination, the brand's rights to the bought-out formula survive; the manufacturer shall deliver the full formula file (INCI, process, QC standards) within 15 business days."
Leverage: bigger MOQ = more negotiating power. At 500 units, exclusivity is a long shot; above 5,000 units, it's basically negotiable.
Q8: What extra documentation does a sensitive-skin product need to file?
Short answer: Standard filing + human efficacy test + (recommended) patch test.
In the US, ordinary cosmetics don't need pre-market approval (MoCRA adds facility registration + responsible-person + adverse-event reporting, but not pre-market claim approval). But "for sensitive skin" is a claim that needs substantiation.
Why HRIPT matters: the Human Repeat Insult Patch Test is the gold standard for sensitization. Not legally mandated, but if you claim "for sensitive skin" without it, you have zero defensive evidence against an allergic-reaction complaint.
Three compliance points for sensitive-skin formulas: (1) preservative system — favor phenoxyethanol + ethylhexylglycerin; avoid MIT (banned in leave-on in the EU) and formaldehyde releasers; keep total preservative ≤0.3%. (2) No fragrance/colorants in the INCI. (3) Active concentrations — centella asiatica 0.1%–0.5%, ceramide 0.1%–1%, panthenol 1%–3%, bisabolol 0.1%–0.5%.
Practical Checklist: Brand Owner's Advanced OEM Self-Audit
Before signing, audit each item:
- [ ] Formula ownership stated (ODM = factory / OEM = brand)
- [ ] Exclusivity clause written (region / category / time)
- [ ] Modified-formula IP ownership clarified
- [ ] Post-termination formula use agreed
- [ ] Stability report delivery in contract
- [ ] Efficacy-cost ownership clarified (factory / brand / split)
- [ ] Packaging-vs-formula MOQ solution set
- [ ] First-batch SKU structure sound (3–5)
- [ ] Raw-material approach decided (turnkey / toll)
- [ ] Sensitive-skin product planned human efficacy + patch test
- [ ] Preservative system meets sensitive-skin needs
- [ ] Shelf-life basis (stability data) confirmed
Three Common Pitfalls
Pitfall 1 — Verbal promises instead of contract clauses. A sales rep says "this formula is yours alone," but it's not in the contract. Three months later a competitor uses it; the factory points to the contract. Everything rests on the written contract.
Pitfall 2 — Ignoring the shelf-life vs. active-decay contradiction. Your retinol serum claims 3 years, but retinol loses 15%–20% after 6 months. By month 18 the effective concentration may fall below threshold — not a compliance issue, but a reputation killer. Suggest "best used within 6 months of opening" for high-active products.
Pitfall 3 — Efficacy sample no longer matches the filed formula. The brand tweaked the formula during testing; the efficacy report used the old sample. At filing, the formula table and report sample don't match → rejected. Rule: the efficacy sample must exactly match the filed formula; any change requires re-testing.
About QuickOEM: QuickOEM is a global digital matching platform for cosmetic OEM/ODM, connecting quality Chinese factories with brand owners worldwide. We offer formula-library sampling, sampling tracking, MoCRA/EU CPNP filing guidance, efficacy-test liaison, and packaging matching — all in one place. Browse factory formula libraries free, compare quotes, and submit sampling requests online.
🔗 Knowledge base: https://www.quickoem.com/blog?channel=oem_knowledge
📞 Free consultation: https://www.quickoem.com/contact